These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3300537)

  • 1. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function.
    Gasser TC; Ebert SC; Graversen PH; Madsen PO
    Antimicrob Agents Chemother; 1987 May; 31(5):709-12. PubMed ID: 3300537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The pharmacokinetics of ciprofloxacin in patients with renal function of various degrees].
    Yu H; Wang HY; Sun ZM
    Zhonghua Nei Ke Za Zhi; 1994 Jul; 33(7):449-51. PubMed ID: 7867438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function.
    Drusano GL; Weir M; Forrest A; Plaisance K; Emm T; Standiford HC
    Antimicrob Agents Chemother; 1987 Jun; 31(6):860-4. PubMed ID: 3619418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ciprofloxacin in healthy volunteers and patients with impaired kidney function.
    Webb DB; Roberts DE; Williams JD; Asscher AW
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():83-7. PubMed ID: 3804907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of the pharmacology of intravenously administered ciprofloxacin.
    Drusano GL
    Am J Med; 1987 Apr; 82(4A):339-45. PubMed ID: 3578325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
    Nilsen OG; Saltvedt E; Walstad RA; Marstein S
    Am J Med; 1992 Apr; 92(4A):38S-40S. PubMed ID: 1316068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects.
    Shah A; Lettieri J; Blum R; Millikin S; Sica D; Heller AH
    J Antimicrob Chemother; 1996 Jul; 38(1):103-16. PubMed ID: 8858462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose.
    Well M; Naber KG; Kinzig-Schippers M; Sörgel F
    Int J Antimicrob Agents; 1998 Apr; 10(1):31-8. PubMed ID: 9624541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elimination of ciprofloxacin and three major metabolites and consequences of reduced renal function.
    Bergan T; Thorsteinsson SB; Rohwedder R; Scholl H
    Chemotherapy; 1989; 35(6):393-405. PubMed ID: 2612228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function.
    Ohkawa M; Hirano S; Tokunaga S; Motoi I; Shoda R; Ikeda A; Sugata T; Sawaki M; Shimamura M; Okasho A; Kuroda K
    Antimicrob Agents Chemother; 1983 Jan; 23(1):31-5. PubMed ID: 6572490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple-dose pharmacokinetics of cefonicid in patients with impaired renal function.
    Phelps RT; Conte JE
    Antimicrob Agents Chemother; 1986 May; 29(5):913-7. PubMed ID: 3729349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of lomefloxacin in renally compromised patients.
    Blum RA; Schultz RW; Schentag JJ
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2364-8. PubMed ID: 2088191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between renal function and disposition of oral ciprofloxacin.
    Forrest A; Weir M; Plaisance KI; Drusano GL; Leslie J; Standiford HC
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1537-40. PubMed ID: 3190182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
    Reitberg DP; Marble DA; Schultz RW; Whall TJ; Schentag JJ
    Antimicrob Agents Chemother; 1988 Apr; 32(4):503-9. PubMed ID: 3377461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefmenoxime pharmacokinetics in patients with renal insufficiency.
    Polk RE; Sica DA; Kerkering TM; Kline BJ; Patterson PM; Baggett JW
    Antimicrob Agents Chemother; 1984 Sep; 26(3):322-7. PubMed ID: 6095752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.
    Jaehde U; Sörgel F; Reiter A; Sigl G; Naber KG; Schunack W
    Clin Pharmacol Ther; 1995 Nov; 58(5):532-41. PubMed ID: 7586947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function.
    Kowalsky SF; Echols RM; Venezia AR; Andrews EA
    Antimicrob Agents Chemother; 1983 Aug; 24(2):151-5. PubMed ID: 6314884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship.
    Kleinbloesem CH; van Brummelen P; van Harten J; Danhof M; Breimer DD
    Clin Pharmacol Ther; 1985 May; 37(5):563-74. PubMed ID: 3987180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of ciprofloxacin in cystic fibrosis.
    Davis RL; Koup JR; Williams-Warren J; Weber A; Heggen L; Stempel D; Smith AL
    Antimicrob Agents Chemother; 1987 Jun; 31(6):915-9. PubMed ID: 3619423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cefpiramide in volunteers with normal or impaired renal function.
    Conte JE
    Antimicrob Agents Chemother; 1987 Oct; 31(10):1585-8. PubMed ID: 3435107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.